Evidence to support the therapeutic potential of bacteriophage Kpn5 in burn wound infection caused by Klebsiella pneumoniae in BALB/c mice.
The emergence of antibiotic-resistant bacterial strains is one of the most critical problems of modern medicine. Bacteriophages have been suggested as an alternative therapeutic agent for such bacterial infections. In the present study, we examined the therapeutic potential of phage Kpn5 in the treatment of Klebsiella pneumoniae B5055-induced burn wound infection in a mouse model. An experimental model of contact burn wound infection was established in mice employing K. pneumoniae B5055 to assess the efficacy of phage Kpn5 in vivo. Survival and stability of phage Kpn5 were evaluated in mice and the maximum phage count in various organs was obtained at 6 h and persisted until 36 h. The Kpn5 phage was found to be effective in the treatment of Klebsiella-induced burn wound infection in mice when phage was administered immediately after bacterial challange. Even when treatment was delayed up to 18 h post infection, when all animals were moribund, approximately 26.66% of the mice could be rescued by a single injection of this phage preparation. The ability of this phage to protect bacteremic mice was demonstrated to be due to the functional capabilities of the phage and not due to a nonspecific immune effect. The levels of pro-inflammatory cytokines (IL-1beta and TNF-alpha) and anti-inflammatory cytokines (IL-10) were significantly lower in sera and lungs of phage-treated mice than phage untreated control mice. The results of the present study bring out the potential of bacteriophage therapy as an alternate preventive approach to treat K. pneumoniae B5055- induced burn wound infections. This approach not only helps in the clearance of bacteria from the host but also protects against the ensuing inflammatory damage due to the exaggerated response seen in any infectious process.
Basic Medical Sciences Building, Department of Microbiology, Panjab University, Chandigarh, India.
Seema
S
Kumari
Kusum
K
Harjai
Sanjay
S
Chhibber
D000818:Animals; D001435:Bacteriophages / Q000502:physiology*; D001691:Biological Therapy; D002056:Burns / Q000150:complications*; D004195:Disease Models, Animal; D006801:Humans; D016753:Interleukin-10 / Q000276:immunology; D007710:Klebsiella Infections / Q000209:etiology / Q000276:immunology / Q000382:microbiology / Q000628:therapy*; D007711:Klebsiella pneumoniae / Q000502:physiology / Q000821:virology*; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D014409:Tumor Necrosis Factor-alpha / Q000276:immunology; D014946:Wound Infection / Q000209:etiology / Q000276:immunology / Q000382:microbiology / Q000628:therapy*
D014409:Tumor Necrosis Factor-alpha; D016753:Interleukin-10